Envista (NVST)

• Market cap: $2.71B
• 1 day: -0.74%
• 5 days: 3.74%
• 1 month: -6.84%
• 3 months: -24.89%
• 6 months: -16.38%
• Year to date: -15.86%
• 1 year: -18.29%
• 5 years: -17.41%
• 10 years: -42.47%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.

Employees: 12,300

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

809% more call options, than puts

Call options by funds: $15.9M | Put options by funds: $1.75M

67% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 5 (+2) [Q4]

2.28% more ownership

Funds ownership: 110.96% [Q3] → 113.24% (+2.28%) [Q4]

0% less capital invested

Capital invested by funds: $3.76B [Q3] → $3.76B (-$3.01M) [Q4]

7% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 41

2% less funds holding

Funds holding: 292 [Q3] → 285 (-7) [Q4]

26% less repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 119

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 6% upside
• Avg. target: $20 24% upside
• High target: $23 43% upside

6 analyst ratings

• positive: 1 17%
• neutral: 5 83%
• negative: 0 0%

Piper Sandler Jason Bednar 32% 1-year accuracy 12 / 38 met price target	6% upside $17	Neutral Maintained	30 Apr 2025
B of A Securities Michael Cherny 71% 1-year accuracy 20 / 28 met price target	43% upside $23	Buy Maintained	29 Apr 2025
UBS Kevin Caliendo 35% 1-year accuracy 6 / 17 met price target	31% upside $21	Neutral Maintained	10 Mar 2025
JP Morgan Rachel Vatnsdal 69% 1-year accuracy 11 / 16 met price target	18% upside $19	Neutral Maintained	6 Mar 2025
Morgan Stanley Erin Wright 54% 1-year accuracy 13 / 24 met price target	18% upside $19	Equal-Weight Maintained	6 Mar 2025